Search Results - "Hompesch, M."

Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles by Krentz, A. J., Fujioka, K., Hompesch, M.

“…Pharmacotherapy directed toward reducing body weight may provide benefits for both curbing obesity and lowering the risk of obesity‐associated comorbidities;…”
Get full text

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin by Devineni, D., Morrow, L., Hompesch, M., Skee, D., Vandebosch, A., Murphy, J., Ways, K., Schwartz, S.

“…Aim: Canagliflozin is a sodium‐glucose co‐transporter 2 (SGLT2) inhibitor that is being investigated for the treatment of type 2 diabetes mellitus (T2DM)…”
Get full text

Biosimilar insulins: guidance for data interpretation by clinicians and users by Heinemann, L., Home, P. D., Hompesch, M.

“…Biosimilar insulins are approved copies of insulins outside patent protection. Advantages may include greater market competition and potential cost reduction,…”
Get full text

Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus by Hompesch, M., Jones-Leone, A., Carr, M. C., Matthews, J., Zhi, H., Young, M., Morrow, L., Reinhardt, R. R.

“…Aim To determine if the glucagon‐like peptide‐1 (GLP‐1) receptor agonist albiglutide, once weekly, impairs counter‐regulatory responses during hypoglycaemia…”
Get full text

Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes by Heise, T., Morrow, L., Hompesch, M., Häring, H.-U., Kapitza, C., Abt, M., Ramsauer, M., Magnone, M.-C., Fuerst-Recktenwald, S.

“…Aims We assessed safety and efficacy of two selective 11β‐HSD1 inhibitors (RO5093151/RO‐151 and RO5027383/RO‐838) in this randomized, controlled study in…”
Get full text

novel insulin formulation with a more rapid onset of action by Steiner, S, Hompesch, M, Pohl, R, Simms, P, Flacke, F, Mohr, T, Pfützner, A, Heinemann, L

“…Aims/hypothesis This study evaluates the pharmacodynamic and pharmacokinetic properties of the novel ultra-fast insulin product VIAject, a formulation of human…”
Get full text

Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction by Morrow, L, Hompesch, M, Guthrie, H, Chang, D, Chatterjee, D.J

“…Aim: To compare the pharmacokinetic (PK) [area under the curve (AUC₀₋₂₄ h, Cmax)] and pharmacodynamic (PD) (AUCGIR ₀₋₂₄ h, GIRmax) properties of single-dose…”
Get full text

Glucodynamics of long-acting basal insulin peglispro compared with insulin glargine at steady state in patients with type 1 diabetes: substudy of a randomized crossover trial by Morrow, L. A., Hompesch, M., Jacober, S. J., Leng Choi, S., Qu, Y., Sinha, V. P.

“…Aims To compare, in an open‐label, randomized, crossover phase II substudy, the glucodynamics of insulin glargine and those of basal insulin peglispro (BIL) in…”
Get full text

Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin by Krentz, A. J., Morrow, L., Petersson, M., Norjavaara, E., Hompesch, M.

“…Aims To study the effect of exogenous i.m. glucagon on recovery from controlled insulin‐induced hypoglycaemia in patients with type 2 diabetes treated with the…”
Get full text

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes by Nauck, M A, Hompesch, M, Filipczak, R, Le, T D T, Zdravkovic, M, Gumprecht, J

“…Effects of the long acting GLP-1 analogue--liraglutide in subjects with type 2 diabetes. 144 type 2 diabetic subjects on metformin treatment (1000 mg BID) were…”
Get more information

Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus by Morrow, L. A., Leonsson-Zachrisson, M., Ericsson, H., Wollbratt, M., Knutsson, M., Hompesch, M., Norjavaara, E.

“…Aims To assess the safety, pharmacokinetics and pharmacodynamics of multiple‐ascending doses of the novel glucokinase activator AZD1656 in patients with type 2…”
Get full text

Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes by Ocheltree, S M, Hompesch, M, Wondmagegnehu, E T, Morrow, L, Win, K, Jacober, S J

“…ObjectiveThe objective of the study was to evaluate pharmacodynamic (PD) intrasubject variability of a single, s.c. dose of insulin lispro protamine suspension…”
Get full text

Short-term metabolic effects of prednisone administration in healthy subjects by Kauh, E. A., Mixson, L. A., Shankar, S., McCarthy, J., Maridakis, V., Morrow, L., Heinemann, L., Ruddy, M. K., Herman, G. A., Kelley, D. E., Hompesch, M.

“…Aims: Supraphysiologic glucocorticoid activity is well established to cause impaired glucose tolerance and insulin resistance, yet no study has evaluated…”
Get full text

Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups by Hompesch, M., Troupin, B., Heise, T., Elbroend, B., Endahl, L., Haahr, H., Heinemann, L.

“…Aim:  To evaluate the time‐action profiles and the dose–response relationship of the long‐acting insulin analogues insulin detemir (IDet) and NPH insulin (NPH)…”
Get full text

A phase 1, open-label, single-dose study to evaluate the pharmacokinetics (PK), safety and tolerability of HM15912 in subjects with severe renal impairment (RI) and normal renal function by Kim, M., Nam, P., Kim, S., Lee, M.H., Hompesch, M.

Get full text

Evaluation of performance of a continuous glucose measurement device in subjects with type 1 and type 2 diabetes by means of a glucose clamp (hypoglycemia performance feasibility) by Morrow, L, Hompesch, M, Tideman, A, Matson, J, Pardo, S, Parkes, J.L, Schachner, H, Simmons, D.A

Get full text

alpha-Lipoic acid in NIDDM patients with cardiac autonomic neuropathy by Köbberling, J, Hompesch, M

Get full text

Exploring the insulin secretory properties of the PGD(2)-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patients by Skrtic, Stanko, Tyrberg, B., Broberg, M., Ericsson, H., Schnecke, V., Kjaer, M., Hompesch, M., Andersson, E. M., Ryberg, E., Aivazidis, A., Huldt, C. W., Lofgren, L., Morrow, L., Parkinson, J., Ryden-Bergsten, T., Watkins, E., Winzell, M. S.

“…Aims/Hypothesis GPR44 (DP2, PTGDR2, CRTh2) is the receptor for the pro-inflammatory mediator prosta-glandin D-2 (PGD(2)) and it is enriched in human islets. In…”
Get full text

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes by Schnell, Oliver, Battelino, Tadej, Bergenstal, Richard, Birkenfeld, Andreas L, Ceriello, Antonio, Cheng, Alice, Davies, Melanie, Edelman, Steve, Forst, Thomas, Giorgino, Francesco, Green, Jennifer, Groop, Per-Henrik, Hadjadj, Samy, J L Heerspink, Hiddo, Hompesch, Marcus, Izthak, Baruch, Ji, Linong, Kanumilli, Naresh, Mankovsky, Boris, Mathieu, Chantal, Miszon, Martin, Mustafa, Reem, Nauck, Michael, Pecoits-Filho, Roberto, Pettus, Jeremy, Ranta, Kari, Rodbard, Helena W, Rossing, Peter, Ryden, Lars, Schumm-Draeger, Petra-Maria, Solomon, Scott D, Škrha, Jan, Topsever, Pinar, Vilsbøll, Tina, Wilding, John, Standl, Eberhard

“…The 8th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Kidney, and Glycemic Outcomes was held virtually on November 10-12, 2022. Following the…”
Get full text

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes by Sha, Sue, Devineni, Damayanthi, Ghosh, Atalanta, Polidori, David, Hompesch, Marcus, Arnolds, Sabine, Morrow, Linda, Spitzer, Heike, Demarest, Keith, Rothenberg, Paul

“…This randomized, double-blind, placebo-controlled, single and multiple ascending-dose study evaluated the pharmacodynamic effects and safety/tolerability of…”
Get full text